Redx Pharma secures $1m grant for bacteria research
Redx Pharma has secured a $1m grant fromCARB-X, one of the world’s largest public-private partnerships, launched in July 2016 to speed up global antibacterial innovation and research.
The 11 successful projects were selected through a competitive process from 168 applications from around the world. The awarded grants were based on the merits of each of the company’s research proposals, as evaluated by the CARB-X Advisory Board and the CARB-X team.
Today’s announcement by CARB-X showcases the first projects selected for the Powered by CARB-X portfolio, spotlighting Redx as a highly-respected partner of choice on a global stage.
Redx will receive US$1 million over 18 months, with an option for future tiered milestone payments, to drive scientific progress against globally challenging drug resistant Gram-negative bacteria.
This collaboration with CARB-X enables Redx to move its Gram-negative program into the next stage of development with a prospective partner.
Dr Neil Murray, Chief Executive Officer of Redx Pharma, said: “We are delighted to be collaborating with CARB-X, a truly innovative initiative that is targeting the development of new life-saving antibacterials and diagnostics. Receiving this grant today is testament to the great science that exists at Redx.
“This grant cements a path forward for our recently announced strategy, to secure external partners to ensure that our high quality anti-infective science will continue whilst we sharpen our focus on the clinical development of our oncology and immunology programs.”
Source: Company Press Release